P
TEVA icon

Pitcairn’s Teva Pharmaceuticals TEVA Stock Holding History

Pitcairn’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,651
Closed -$1.04M – 518
2025
Q3 		$1.04M Sell
51,651
-12,598
-20% -$221K 0.08% 214
2025
Q2 		$1.08M Buy
64,249
+2,266
+4% +$36.6K 0.07% 243
2025
Q1 		$953K Buy
61,983
+1,096
+2% +$19.6K 0.06% 284
2024
Q4 		$1.34M Buy
60,887
+8,312
+16% +$151K 0.08% 216
2024
Q3 		$947K Buy
+52,575
New +$920K 0.06% 283
2016
Q4 		– Sell
-13,790
Closed -$635K – 521
2016
Q3 		$635K Buy
+13,790
New +$719K 0.08% 200
2016
Q2 		– Sell
-12,313
Closed -$659K – 478
2016
Q1 		$659K Sell
12,313
-458
-4% -$26.9K 0.08% 194
2015
Q4 		$839K Buy
+12,771
New +$789K 0.09% 160

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Pitcairn's TEVA Position: Q4 2025 in Review

Pitcairn sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 51,651 shares — an estimated $1.04M sold.

Pitcairn first reported a position in TEVA in Q4 2015 and held it in 8 quarters. The position peaked at $1.34M in Q4 2024. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Pitcairn reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 51,651 Teva Pharmaceuticals shares in Q4 2025, an estimated $1.04M.
  • Pitcairn first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Pitcairn's Teva Pharmaceuticals position peaked at $1.34M in Q4 2024.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.